193 related articles for article (PubMed ID: 29163796)
1. Plasminogen activator inhibitor-1 is an independent prognostic factor of ovarian cancer and IMD-4482, a novel plasminogen activator inhibitor-1 inhibitor, inhibits ovarian cancer peritoneal dissemination.
Nakatsuka E; Sawada K; Nakamura K; Yoshimura A; Kinose Y; Kodama M; Hashimoto K; Mabuchi S; Makino H; Morii E; Yamaguchi Y; Yanase T; Itai A; Morishige KI; Kimura T
Oncotarget; 2017 Oct; 8(52):89887-89902. PubMed ID: 29163796
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients.
Chambers SK; Ivins CM; Carcangiu ML
Int J Cancer; 1998 Oct; 79(5):449-54. PubMed ID: 9761111
[TBL] [Abstract][Full Text] [Related]
3. The significance of urokinase- type plasminogen activator, its inhibitors, and its receptor in ascites of patients with epithelial ovarian cancer.
Chambers SK; Gertz RE; Ivins CM; Kacinski BM
Cancer; 1995 Apr; 75(7):1627-33. PubMed ID: 8826920
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor-beta1 produced by ovarian cancer cell line HRA stimulates attachment and invasion through an up-regulation of plasminogen activator inhibitor type-1 in human peritoneal mesothelial cells.
Hirashima Y; Kobayashi H; Suzuki M; Tanaka Y; Kanayama N; Terao T
J Biol Chem; 2003 Jul; 278(29):26793-802. PubMed ID: 12743121
[TBL] [Abstract][Full Text] [Related]
5. The Novel IκB Kinase β Inhibitor, IMD-0560, Has Potent Therapeutic Efficacy in Ovarian Cancer Xenograft Model Mice.
Sawada I; Hashimoto K; Sawada K; Kinose Y; Nakamura K; Toda A; Nakatsuka E; Yoshimura A; Mabuchi S; Fujikawa T; Itai A; Kimura T
Int J Gynecol Cancer; 2016 May; 26(4):610-8. PubMed ID: 26905334
[TBL] [Abstract][Full Text] [Related]
6. Is there a role for urokinase-type plasminogen activator inhibitors as maintenance therapy in patients with ovarian cancer?
van Dam PA; Coelho A; Rolfo C
Eur J Surg Oncol; 2017 Feb; 43(2):252-257. PubMed ID: 27345498
[TBL] [Abstract][Full Text] [Related]
7. Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
Clin Cancer Res; 2001 Jun; 7(6):1743-9. PubMed ID: 11410515
[TBL] [Abstract][Full Text] [Related]
8. Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance.
Zhang W; Ling D; Tan J; Zhang J; Li L
Oncol Rep; 2013 Feb; 29(2):637-45. PubMed ID: 23174953
[TBL] [Abstract][Full Text] [Related]
9. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation.
Kjøller L; Kanse SM; Kirkegaard T; Rodenburg KW; Rønne E; Goodman SL; Preissner KT; Ossowski L; Andreasen PA
Exp Cell Res; 1997 May; 232(2):420-9. PubMed ID: 9168821
[TBL] [Abstract][Full Text] [Related]
10. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading.
Planus E; Barlovatz-Meimon G; Rogers RA; Bonavaud S; Ingber DE; Wang N
J Cell Sci; 1997 May; 110 ( Pt 9)():1091-8. PubMed ID: 9175705
[TBL] [Abstract][Full Text] [Related]
11. The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
Zhu C; Jiang L; Xu J; Ren A; Ju F; Shu Y
Pathol Res Pract; 2020 Apr; 216(4):152885. PubMed ID: 32113794
[TBL] [Abstract][Full Text] [Related]
12. [Expression and clinical significance of uPA and PAI-1 in epithelial ovarian cancer].
Cai Z; Li YF; Liu FY; Feng YL; Hou JH; Zhao MQ
Ai Zheng; 2007 Mar; 26(3):312-7. PubMed ID: 17355798
[TBL] [Abstract][Full Text] [Related]
13. IKKβ Regulates VEGF Expression and Is a Potential Therapeutic Target for Ovarian Cancer as an Antiangiogenic Treatment.
Kinose Y; Sawada K; Makino H; Ogura T; Mizuno T; Suzuki N; Fujikawa T; Morii E; Nakamura K; Sawada I; Toda A; Hashimoto K; Isobe A; Mabuchi S; Ohta T; Itai A; Morishige K; Kurachi H; Kimura T
Mol Cancer Ther; 2015 Apr; 14(4):909-19. PubMed ID: 25637316
[TBL] [Abstract][Full Text] [Related]
14. Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor related to the actions of CSF-1.
Chambers SK; Ivins CM; Carcangiu ML
Int J Cancer; 1997 Dec; 74(6):571-5. PubMed ID: 9421350
[TBL] [Abstract][Full Text] [Related]
15. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system.
Heiss MM; Babic R; Allgayer H; Gruetzner KU; Jauch KW; Loehrs U; Schildberg FW
J Clin Oncol; 1995 Aug; 13(8):2084-93. PubMed ID: 7636552
[TBL] [Abstract][Full Text] [Related]
16. Plasminogen Activator Inhibitor Type 1 in Blood at Onset of Chemotherapy Unfavorably Affects Survival in Primary Ovarian Cancer.
Teliga-Czajkowska J; Sienko J; Jalinik K; Derlatka P; Danska-Bidzinska A; Czajkowski K
Adv Exp Med Biol; 2019; 1153():47-54. PubMed ID: 30924028
[TBL] [Abstract][Full Text] [Related]
17. IMD-4690, a novel specific inhibitor for plasminogen activator inhibitor-1, reduces allergic airway remodeling in a mouse model of chronic asthma via regulating angiogenesis and remodeling-related mediators.
Tezuka T; Ogawa H; Azuma M; Goto H; Uehara H; Aono Y; Hanibuchi M; Yamaguchi Y; Fujikawa T; Itai A; Nishioka Y
PLoS One; 2015; 10(3):e0121615. PubMed ID: 25785861
[TBL] [Abstract][Full Text] [Related]
18. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
[TBL] [Abstract][Full Text] [Related]
19. Expression of urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in benign, borderline, malignant primary and metastatic ovarian tumors.
van der Burg ME; Henzen-Logmans SC; Berns EM; van Putten WL; Klijn JG; Foekens JA
Int J Cancer; 1996 Dec; 69(6):475-9. PubMed ID: 8980250
[TBL] [Abstract][Full Text] [Related]
20. Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.
Ito H; Yonemura Y; Fujita H; Tsuchihara K; Kawamura T; Nojima N; Fujimura T; Nose H; Endo Y; Sasaki T
Virchows Arch; 1996 Feb; 427(5):487-96. PubMed ID: 8624578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
